The future of mesothelioma treatment: time to shift gear
Mené dans 27 pays sur 458 patients atteints d'un mésothéliome pleural malin non résécable de stade avancé, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du nintédanib à un traitement combinant pémétrexed et cisplatine
As of May 2019, the standard treatment regimen for unresectable pleural mesothelioma still consists of a platinum-based drug plus pemetrexed, first described by Vogelzang and colleagues in 2003. The median overall survival of patients with unresectable pleural mesothelioma remains around 1 year, which is far from satisfactory. Thus, new and more effective treatments for patients who have this highly aggressive and lethal malignancy with very few treatment options are eagerly awaited.